# OnCo record nct07707895 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07707895/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07707895", "NCT07707895" ;
  schema:name "DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers"@en ;
  schema:description "A phase 1/2 trial of obrixtamig, ZL-1310 and atezolizumab in lung cancer, run by Boehringer Ingelheim, not yet recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07707895/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07707895> ;
  onco:status "planned" ;
  onco:tag "ctgov-ingest", "lung-deep-dive" ;
  onco:phase "1/2" ;
  onco:cancers <https://onco.cc/cancers/sclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/obrixtamig/>, <https://onco.cc/drugs/zl-1310/>, <https://onco.cc/drugs/atezolizumab/> ;
  onco:companies <https://onco.cc/companies/boehringer-ingelheim/> .